Patients with cancer could be willing to wait for greater certainty of the benefit of new cancer drugs before they are approved by the U.S. Food and Drug Administration (FDA), suggests a new study from the London School of Economics and Political Science (LSE), published in The Lancet Oncology.
Not all patients want faster cancer drug approvals without certainty they work
